| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 3.6K | 3.5% | 10.4% |
| Total Income | 3.6K | 3.9% | 10.1% |
| Expenditure | 3.0K | 4.4% | 7.6% |
| PBT | 505.79 | 18.6% | 2.4% |
| Net Profit | 413.88 | 20.4% | 7.6% |
| OPM | 22.79% | 2.13pp | 22.69pp |
| NPM | 11.37% | 2.36pp | 0.15pp |
| EPS | 9.90 | 20.1% | 4.8% |
Mankind Pharma Reports 11.5% YoY Revenue Growth in Q3FY26, Adj. EBITDA Margin at 25.9%
03 Feb 2026 · 3 Feb, 4:24 pm
Summary
Mankind Pharma, India's fourth largest pharmaceutical Company, has announced its financial results for the third quarter and nine months ended 31st December 2025. The Company's revenue increased by 11.5% YoY, with adj. EBITDA margins of 25.9%. The chronic share increased by 200bps YoY to 39.3% driven by strong growth of 16.7% in cardiac and 14.4% in anti-diabetes. Revenue from OTC grew by 5.2% in Q3FY26 vs -2.6% in Q2FY26.
Key Highlights
- 1
Revenue from Operations at INR 3,567 Cr, up by 11.5% YoY
- 2
Domestic revenue at INR 3,046 Cr, up 11.1%, Exports at INR 521 Cr, up 14.1% YoY
- 3
Adjusted EBITDA margin of 25.9% and PAT margin of 11.6%
- 4
Diluted EPS of INR 9.9 up by 6.7% YoY (FV Re.1)
- 5
Domestic revenue registered a growth of 11.1% YoY driven by growth in base business, further aided by BSV consolidation
- 6
Secondary sales growth of 8.5% vs 11.8% IPM — primarily due to underperformance in acute therapies amid ongoing corrective actions
- 7
Strong performance in chronic growth with 16.7% growth in Cardiac and 14.4% in Anti- Diabetics
- 8
Revenue growth of 5.2% YoY in Q3FY26 vs -2.6% in Q2FY26, regaining sequential growth momentum
- 9
Revenue growth of 14% YoY primarily driven by healthy growth in BSV international business
Management Comments
Mr. Rajeev Juneja — Vice Chairman & Managing Director
Mankind’s revenue increased 11.5% YoY, with adj. EBITDA margins of 25.9%, primarily due to improvement in domestic pharma and BSV consolidation. Mankind’s chronic share increased by 200bps YoY to 39.3% driven by strong growth of 16.7% in cardiac and 14.4% in anti-diabetes. Revenue from OTC grew by 5.2% in Q3FY26 vs -2.6% in Q2FY26. We expect growth to improve further. BSV growth initiatives progressing well; Strong double-digit growth in Q3. We remain confident of delivering long term sustainable growth anchored by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio.”
Informational and educational content only. Not investment advice.